Naomi Y Ko1,2, Susan Hong3, Robert A Winn4, Gregory S Calip3,5. 1. Hematology and Medical Oncology, Boston University School of Medicine, Boston, Massachusetts. 2. Boston Medical Center, Boston, Massachusetts. 3. Cancer Prevention and Control Program, University of Illinois Cancer Center, Chicago. 4. Massey Cancer Center, Virginia Commonwealth University, Richmond. 5. Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
Importance: Compared with non-Hispanic white women, racial/ethnic minority women receive a diagnosis of breast cancer at a more advanced stage and have higher morbidity and mortality with breast cancer diagnosis. Access to care with adequate insurance may be associated with earlier diagnosis, expedited treatment, and improved prognosis. Objective: To examine the extent to which insurance is associated with access to timely breast cancer diagnosis and breast cancer stage differences among a large, diverse population of US patients with breast cancer. Design, Setting, and Participants: This retrospective, cross-sectional population-based study used data from the Surveillance, Epidemiology, and End Results Program on 177 075 women aged 40 to 64 years who received a diagnosis of stage I to III breast cancer between January 1, 2010, and December 31, 2016. Statistical analysis was performed from August 1, 2017, to October 1, 2019. Main Outcomes and Measures: The primary outcome was the risk of having a more advanced stage of breast cancer at diagnosis (ie, stage III vs stages I and II). Mediation analyses were conducted to determine associations of race/ethnicity and proportion of observed differences mediated by health insurance status with earlier stage of diagnosis. Results: A total of 177 075 women (mean [SD] age, 53.5 [6.8] years; 148 124 insured and 28 951 uninsured or receiving Medicaid) were included in the study. A higher proportion of women either receiving Medicaid or who were uninsured received a diagnosis of locally advanced breast cancer (stage III) compared with women with health insurance (20% vs 11%). In multivariable models, non-Hispanic black (odds ratio [OR], 1.46 [95% CI, 1.40-1.53]), American Indian or Alaskan Native (OR, 1.31 [95% CI, 1.07-1.61]) and Hispanic (OR, 1.35 [95% CI, 1.30-1.42]) women had higher odds of receiving a diagnosis of locally advanced disease (stage III) compared with non-Hispanic white women. When adjusting for health insurance and other socioeconomic factors, associations between race/ethnicity and risk of locally advanced breast cancer were attenuated (non-Hispanic black: OR, 1.29 [95% CI, 1.23-1.35]; American Indian or Alaskan Native: OR, 1.11 [95% CI, 0.91-1.35]; Hispanic: OR, 1.17 [95% CI, 1.12-1.22]). Nearly half (45%-47%) of racial differences in the risk of locally advanced disease were mediated by health insurance. Conclusions and Relevance: This study's findings suggest that nearly half of the observed racial/ethnic disparities in higher stage at breast cancer diagnosis are mediated by health insurance coverage.
Importance: Compared with non-Hispanic white women, racial/ethnic minority women receive a diagnosis of breast cancer at a more advanced stage and have higher morbidity and mortality with breast cancer diagnosis. Access to care with adequate insurance may be associated with earlier diagnosis, expedited treatment, and improved prognosis. Objective: To examine the extent to which insurance is associated with access to timely breast cancer diagnosis and breast cancer stage differences among a large, diverse population of US patients with breast cancer. Design, Setting, and Participants: This retrospective, cross-sectional population-based study used data from the Surveillance, Epidemiology, and End Results Program on 177 075 women aged 40 to 64 years who received a diagnosis of stage I to III breast cancer between January 1, 2010, and December 31, 2016. Statistical analysis was performed from August 1, 2017, to October 1, 2019. Main Outcomes and Measures: The primary outcome was the risk of having a more advanced stage of breast cancer at diagnosis (ie, stage III vs stages I and II). Mediation analyses were conducted to determine associations of race/ethnicity and proportion of observed differences mediated by health insurance status with earlier stage of diagnosis. Results: A total of 177 075 women (mean [SD] age, 53.5 [6.8] years; 148 124 insured and 28 951 uninsured or receiving Medicaid) were included in the study. A higher proportion of women either receiving Medicaid or who were uninsured received a diagnosis of locally advanced breast cancer (stage III) compared with women with health insurance (20% vs 11%). In multivariable models, non-Hispanic black (odds ratio [OR], 1.46 [95% CI, 1.40-1.53]), American Indian or Alaskan Native (OR, 1.31 [95% CI, 1.07-1.61]) and Hispanic (OR, 1.35 [95% CI, 1.30-1.42]) women had higher odds of receiving a diagnosis of locally advanced disease (stage III) compared with non-Hispanic white women. When adjusting for health insurance and other socioeconomic factors, associations between race/ethnicity and risk of locally advanced breast cancer were attenuated (non-Hispanic black: OR, 1.29 [95% CI, 1.23-1.35]; American Indian or Alaskan Native: OR, 1.11 [95% CI, 0.91-1.35]; Hispanic: OR, 1.17 [95% CI, 1.12-1.22]). Nearly half (45%-47%) of racial differences in the risk of locally advanced disease were mediated by health insurance. Conclusions and Relevance: This study's findings suggest that nearly half of the observed racial/ethnic disparities in higher stage at breast cancer diagnosis are mediated by health insurance coverage.
Authors: Achal Patel; Montserrat García-Closas; Andrew F Olshan; Charles M Perou; Melissa A Troester; Michael I Love; Arjun Bhattacharya Journal: Cancer Res Date: 2021-10-28 Impact factor: 12.701
Authors: Kenneth A Fleming; Susan Horton; Michael L Wilson; Rifat Atun; Kristen DeStigter; John Flanigan; Shahin Sayed; Pierrick Adam; Bertha Aguilar; Savvas Andronikou; Catharina Boehme; William Cherniak; Annie Ny Cheung; Bernice Dahn; Lluis Donoso-Bach; Tania Douglas; Patricia Garcia; Sarwat Hussain; Hari S Iyer; Mikashmi Kohli; Alain B Labrique; Lai-Meng Looi; John G Meara; John Nkengasong; Madhukar Pai; Kara-Lee Pool; Kaushik Ramaiya; Lee Schroeder; Devanshi Shah; Richard Sullivan; Bien-Soo Tan; Kamini Walia Journal: Lancet Date: 2021-10-06 Impact factor: 79.321
Authors: Lauren Groskaufmanis; Paul Lin; Neil Kamdar; Anam Khan; Mark D Peterson; Michelle Meade; Elham Mahmoudi Journal: Ann Fam Med Date: 2022 Sep-Oct Impact factor: 5.707
Authors: Elizabeth S Ver Hoeve; Melissa A Simon; Sankirtana M Danner; Antonio J Washington; Susan D Coples; Sanja Percac-Lima; Emma C Whited; Electra D Paskett; Michelle J Naughton; Darrell M Gray; Jennifer A Wenzel; James R Zabora; Ahmed Hassoon; Elliott E Tolbert; Elizabeth Calhoun; Debra L Barton; Christopher R Friese; Marita G Titler; Heidi A Hamann Journal: Cancer Date: 2022-05-17 Impact factor: 6.921
Authors: Tess Thompson; Maria Pérez; Yan Yan; Matthew W Kreuter; Julie A Margenthaler; Graham A Colditz; Donna B Jeffe Journal: Soc Sci Med Date: 2020-12-29 Impact factor: 4.634
Authors: Neal G Spada; Emily M Geramita; Maryam Zamanian; G J van Londen; Zhaojun Sun; Lindsay M Sabik Journal: J Womens Health (Larchmt) Date: 2020-09-28 Impact factor: 2.681
Authors: Eduardo R Núñez; Tanner J Caverly; Sanqian Zhang; Mark E Glickman; Shirley X Qian; Jacqueline H Boudreau; Christopher G Slatore; Donald R Miller; Renda Soylemez Wiener Journal: JAMA Netw Open Date: 2021-07-01